Joint Pain Forum – News you can use!
NicOx begins third final-phase naproxcinod trial
Fri Jun 29, 2007
NicOx has begun a third final-stage clinical study testing its
experimental anti-inflammatory drug naproxcinod in patients with
osteoarthritis of the hip, the French biotechnology company said on
Friday. NicOx expected the results of this study and an earlier one on
patients with osteoarthritis in the knee by mid-2008. NicOx plans to
submit naproxcinod for U.S. and European Union marketing approval in
the first quarter of 2009.
The company's shares rose as much as 3.2 percent and were up 1 percent at 18.25 euros by 1036 GMT.
About 800 patients at around 100 clinical centres in North America and
Europe are expected to take part in the trial that will compare
naproxcinod with placebo.
The trial aims to show naproxcinod can relieve the signs and symptoms
of osteoarthritis of the hip and to provide additional safety data,
mainly confirming it has no detrimental effect on blood pressure
compared to current treatments.
Current anti-inflammatory treatments -- non steroidal
anti-inflammatory drug (NSAIDs) -- have been linked to higher blood
pressure which could lead to heart attacks and strokes.
"NicOx believes that naproxcinod has the potential to
become the drug of choice for treating osteoarthritis, based on its
unique profile that shows no detrimental effects on blood pressure and
a good gastrointestinal tolerability," it said in a statement.
Map | CONTACT